Oral Acyclovir for Treatment of First-Episode Herpes Simplex Virus Proctitis
- Ann M. Rompalo, MD;
- Gregory J. Mertz, MD;
- L. Gray Davis, MS;
- Jacqueline Benedetti, PhD;
- Cathy Critchlow, MS;
- Walter E. Stamm, MD;
- Lawrence Corey, MD
- From the Departments of Medicine (Drs Rompalo, Mertz, Benedetti, Stamm, and Corey and Ms Critchlow), Laboratory Medicine (Drs Mertz and Corey), and Microbiology (Dr Corey), School of Medicine, and the Department of Biostatistics, School of Public Health and Community Medicine (Dr Benedetti and Ms Critchlow), University of Washington, Seattle; and the Burroughs Wellcome Company, Research Triangle Park, NC (Mr Davis). Dr Mertz is now with the Department of Medicine, University of New Mexico School of Medicine, Albuquerque.
Abstract
Twenty-nine patients with first-episode rectal herpes simplex virus infection were enrolled in a double-blind trial of oral acyclovir, 400 mg five times daily, vs placebo treatment. Eighty percent of those receiving acyclovir compared with 25% of placebo recipients no longer had herpes simplex virus isolated from their rectal lesions three days after onset of therapy. The median duration of rectal lesions and viral excretion from rectal lesions (median, five and zero days, respectively) was significantly shorter in patients treated with acyclovir than in placebo-treated patients (14 and 11 days, respectively). Durations of local signs and symptoms of proctitis, such as rectal pain, discharge, and friability, were shorter in acyclovir recipients than in placebo recipients, but these differences were not statistically significant. Daily administration of 2 g of oral acyclovir for ten days alleviates some of the clinical signs of herpes simplex virus rectal infection.
(JAMA 1988;259:2879-2881)
Footnotes
-
Reprints not available.
